bortezomib + ganciclovir

Bortezomib + ganciclovir is an investigational combination therapy consisting of two small molecule drugs with distinct mechanisms of action. Bortezomib is a reversible proteasome inhibitor primarily used in the treatment of multiple myeloma and mantle cell lymphoma, where it disrupts protein degradation pathways, leading to apoptosis in malignant cells. Ganciclovir is an antiviral nucleoside analogue that inhibits viral DNA polymerase, preventing replication of viruses such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV). The combination has been studied for its potential synergistic effects in treating relapsed or refractory EBV-positive lymphomas, leveraging bortezomib’s ability to induce lytic viral gene expression and sensitize tumor cells to the antiviral activity of ganciclovir[4].